Laboratory Markers and Endoscopic Predictors of Response to Azathioprine in a Cohort of Egyptian Patients with Ulcerative Colitis: A single-center study

 Authors

1 Tropical Medicine and Infectious Diseases Department, Faculty of Medicine, Tanta University, Tanta, Egypt.

2 Public Health and Community Medicine Department, Faculty of Medicine, Menoufia University, Menoufia, Egypt.

3 Tropical Medicine and Infectious Diseases Department, Faculty of Medicine, Tanta University, Tanta, Egypt

4 Clinical and Molecular Parasitology Department, National Liver Institute, Menoufia University, Menoufia, Egypt.

10.21608/ajgh.2026.524999.1107

Abstract

 Aims: Azathioprine (AZA) has been a primary treatment for inflammatory bowel diseases (IBDs), offering steroid-free long-term remission. This study aimed to assess predictors of response to AZA therapy in Egyptian patients diagnosed with ulcerative colitis (UC), to individualize treatment options and avoid the side effects of ineffective drugs.
Patients and methods: We conducted this retrospective study at the Tropical Medicine and Infectious Diseases Department, Tanta University. We reviewed baseline data for patients diagnosed with UC to identify those who had completed six months of AZA therapy for inclusion.
Results: UC patients who received AZA therapy (n = 113) were categorized into 2 groups: 60 (53.1%) were AZA responders, and 53 (46.9%) were non-responders. AZA responders differed significantly in endoscopic findings, histopathology, and steroid use (P < 0.001). We assessed basal laboratory and endoscopic predictors of response. C-reactive protein (CRP) levels (20 versus 48 mg/dL) and Mayo scores (7.4 ± 1.46 versus 9.84 ± 0.88) were significantly higher in non-responders (P < 0.001), as confirmed by multivariate regression analysis. The Mayo score and fecal calprotectin (FC) could predict non-response to AZA using ROC curve analysis, with cutoff values of ≥8.5 and 587.50 µg/g (area under the curve [AUC] = 0.903 and 0.859; sensitivity = 98.1% and 84.9%; specificity = 76.7% and 81.7%, respectively).
Conclusion: Combining baseline laboratory and endoscopic results, particularly FC, CRP, and the Mayo score, may help predict the likelihood of response to AZA therapy in UC patients.

Highlights

  • Baseline Mayo score: A baseline Mayo score ≥8.5 strongly predicts azathioprine (AZA) non-response in ulcerative colitis (UC) patients.
  • C-reactive protein (CRP): Elevated baseline serum CRP levels independently predict therapeutic failure and lack of response to azathioprine.
  • Fecal calprotectin (FC): Fecal calprotectin is a robust, non-invasive biomarker for predicting non-response to azathioprine therapy.
  • Personalized clinical utility: Combining these basal endoscopic and laboratory markers helps optimize precision medicine and personalize therapeutic strategies for Egyptian UC patients.

Comments